2-(9H-fluoren-9-ylideneaminooxy)acetic acid | 1447-84-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 芴
• 英文名称: 2-(9H-fluoren-9-ylideneaminooxy)acetic acid
• 英文别名: 9-fluorenylideneaminooxy ethanoic acid；(9-Fluorenylidenaminooxy)-essigsaeure；Fluoren-9-ylidenaminooxyessigsaeure；[(9h-Fluoren-9-Ylideneamino)oxy]acetic Acid；2-(fluoren-9-ylideneamino)oxyacetic acid
• CAS: 1447-84-3
• 化学式: C₁₅H₁₁NO₃
• 分子量: 253.257
• InChiKey: PLACMAVVPYGZGF-UHFFFAOYSA-N

物化性质

• 沸点：
  493.7±47.0 °C(Predicted)
• 密度：
  1.30±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  58.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(9H-fluoren-9-ylideneaminooxy)acetic acid 在 吡啶 、 氯化亚砜 作用下， 以 正戊烷 、 苯 为溶剂， 生成 t-Butyl-fluoren-9-ylidenaminooxyperacetat
  参考文献：
  名称：

  Forrester,A.R. et al., Journal of the Chemical Society. Perkin transactions I, 1979, p. 606 - 611

  摘要：

  DOI：
• 作为产物：
  描述：

  ethyl 2-(9H-fluoren-9-ylideneaminooxy)acetate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 2.0h， 以52%的产率得到2-(9H-fluoren-9-ylideneaminooxy)acetic acid
  参考文献：
  名称：

  X-ray crystal structure and activity of fluorenyl-based compounds as transthyretin fibrillogenesis inhibitors

  摘要：

  Transthyretin (TTR) is a 54 kDa homotetrameric protein that transports thyroxine (T4) and retinol (vitamin A), through its association with retinol binding protein (RBP). Under unknown conditions, it aggregates to form fibrils associated with TTR amyloidosis. Ligands able to inhibit fibril formation have been studied by X-ray crystallography. The use of polyethylene glycol (PEG) instead of ammonium sulphate or citrate has been evaluated as an alternative to obtain new TTR complexes with (R)-3-(9-fluoren-9-ylideneaminooxy)-2-methyl-N-(methylsulfonyl) propionamide (48R(1)) and 2-(9H-fluoren-9-ylideneaminooxy) acetic acid (ES8(2)). The previously described fluorenyl based inhibitors (S)-3-((9H-fluoren-9-ylideneamino)oxy)-2-methylpropanoic acid (6BD) and 3-((9H-fluoren-9-ylideneamino)oxy)propanoic acid (7BD) have been re-evaluated with the changed crystallization method. The new TTR complexes with compounds of the same family show that the 9-fluorenyl motif can occupy alternative hydrophobic binding sites. This augments the potential use of this scaffold to yield a large variety of differently substituted mono-aryl compounds able to inhibit TTR fibril formation.

  DOI：

  10.3109/14756366.2015.1070265

文献信息

• Camptothecin derivatives as chemoradiosensitizing agents
  申请人：Yang Li-Xi

  公开号：US20070093432A1

  公开（公告）日：2007-04-26

  Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.

  基于紫杉醇的化合物通过将该化合物与放射疗法结合在一起向哺乳动物体内施用，对治疗肿瘤具有益处，即使用放射性物质或来自主体外部源的辐射治疗肿瘤。通过在紫杉醇结构周围定位至少一个电子亲和基团来改性基于紫杉醇的化合物，以增强它们与放射疗法结合的价值。还披露了新的基于紫杉醇的化合物，可通过单独或与放射疗法结合使用这些新化合物来治疗癌症。
• CAMPTOTHECIN DERIVATIVES AS CHEMORADIOSENSITIZING AGENTS
  申请人：YANG Li-Xi

  公开号：US20080318873A1

  公开（公告）日：2008-12-25

  Camptothecin-based compounds are useful for treating a neoplasm in mammalian subjects by administering such compound to the subjects in combination with radiotherapy, i.e., the treatment of tumors with radioactive substances or radiation from a source external to the subject. Camptothecin-based compounds are modified by positioning at least one electron-affinic group around the camptothecin structure to enhance their value in combination with radiotherapy. New Camptothecin-based compounds are disclosed that are useful for treating cancer by administering the novel compounds alone or in combination with radiotherapy.

  基于喜树碱的化合物可用于治疗哺乳动物主体中的肿瘤，通过将该化合物与放射治疗结合给予主体治疗，即使用放射性物质或来自主体外部的辐射治疗肿瘤。将至少一个电子亲和基团定位于喜树碱结构周围，以增强其与放射治疗结合的价值而改性基于喜树碱的化合物。揭示了新的基于喜树碱的化合物，可通过单独或与放射治疗结合给予治疗，用于治疗癌症。
• Aminooxyacetic Acid Derivatives
  作者：Alfred Richardson

  DOI：10.1021/jm00336a042

  日期：1964.11
• US7875602B2
  申请人：——

  公开号：US7875602B2

  公开（公告）日：2011-01-25
• US8563537B2
  申请人：——

  公开号：US8563537B2

  公开（公告）日：2013-10-22